TY - CHAP M1 - Book, Section TI - Sentinel Lymph Node Biopsy for Melanoma A1 - Faries, Mark B. A2 - Morita, Shane Y. A2 - Balch, Charles M. A2 - Klimberg, V. Suzanne A2 - Pawlik, Timothy M. A2 - Posner, Mitchell C. A2 - Tanabe, Kenneth K. Y1 - 2018 N1 - T2 - Textbook of Complex General Surgical Oncology AB - Sentinel lymph node (SLN) biopsy is now a standard component of the treatment of many melanomas, and its use is accepted as routine.1,2 So routine, in fact, that the revolutionary nature of its beginning is little remembered. This is appropriate as the technique and the clinical data supporting its use are now both broad and deep. However, even with our familiarity with the procedure, it is important to remember that the technique requires skill and coordination of multiple disciplines and that appropriate selection of candidates for SLN biopsy is necessary. The impact of SLN biopsy has now spread from melanoma to breast cancer, and may become more common in other solid tumors. The benefits it has produced for melanoma patients around the world including more accurate staging and less morbid treatment of regional lymph nodes are remarkable and will ensure that SLN biopsy will continue to be a vital component of melanoma treatment into the future. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1145755896 ER -